Updates are available Correction dated 2024-07-15
Click to view Correction: https://doi.org/10.1038/s41698-024-00633-7
-
Authors
Planchard, David https://orcid.org/0000-0002-1565-8310
Sanborn, Rachel E. https://orcid.org/0000-0003-0542-6054
Negrao, Marcelo V. https://orcid.org/0000-0001-8938-6699
Vaishnavi, Aria https://orcid.org/0000-0002-7814-3234
Smit, Egbert F. https://orcid.org/0000-0002-7329-6995
- License Information
-
More Information
Article History
Received: 6 October 2023
Accepted: 15 February 2024
First Online: 16 April 2024
Change Date: 15 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41698-024-00633-7
Competing interests
: D.P. reports receiving honoraria from Prime Oncology and PeerVoice; and has had a consulting or advisory role for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Roche, Pfizer, Merck Sharp & Dohme Oncology, Celgene, MedImmune, BeiGene, Samsung, AbbVie, Janssen, Seagen, Takeda, ArriVent, Mirati, Pierre Fabre, and Daiichi Sankyo/AstraZeneca; and has received research funding (institutional financial interest, clinical trials research as principal or co-investigator) from AstraZeneca/MedImmune, Bristol Myers Squibb, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi/Aventis, Taiho Pharmaceutical, Daiichi Sankyo, AbbVie, Janssen, ArriVent, Mirati, Pierre Fabre, Seagen, and Takeda. R.S. reports receiving honoraria from AstraZeneca, GameOn!, Illumina, OncLive, and Targeted Oncology; and has had a consulting or advisory role for Amgen, AstraZeneca, EMD Serono, Daiichi Sankyo, G1 Therapeutics, GE HealthCare, Gilead, GlaxoSmithKline, Janssen Oncology, Regeneron, Sanofi Aventis; and has received research funding from Bristol Myers Squibb, Merck, and AstraZeneca. M.N. reports receiving research funding to institution from Mirati, Novartis, Checkmate, Alaunos, AstraZeneca, Pfizer, Genentech, Navire; a consultant or advisory role for Mirati, Merck/MSD, Novartis, Genentech, Sanofi; and other support from Ziopharm Oncology, ApotheCom, Ashfield Healthcare. A.V. reports no conflicts of interest. E.S. reports receiving honoraria from AstraZeneca, Daiichi Sankyo/AstraZeneca, Merck KGaA, and Boehringer Ingelheim; and has had a consulting or advisory role at Lilly, AstraZeneca, Boehringer Ingelheim, Roche/Genentech, Bristol Myers Squibb, Merck KGaA, MSD Oncology, Takeda, Bayer, Novartis, Daiichi Sankyo, and Seagen; and has received research funding from Boehringer Ingelheim, Bayer, Roche/Genentech, AstraZeneca, and Bristol Myers Squibb.
